Member Info for beinthelead

Shows how far our valuation is out of touch with reality.

https://mobile.twitter.com/jaykay_jayk/status/1458077813001670663

I hope not. Like them, we’d be around 18 months away from market.

Lots of posts to say you’re unhappy with a share you’re invested in. The results have been known for a few months. For someone so confident with their lack of performance, you should have sold at 75p. Hell, sell tomorrow before the drop to 55p.

Never a credible rant from ‘investors’ that analyse weekly SP fluctuations, and compare Apple/Tesla stock with an infantile fledgling. Mind boggles.

The launch has not delivered to my expectations. Agreed. The launch was ramped to high heavens by certain posters. This is also as bad as the negativity.

Monkshood has a genuine tone that enjoy reading. Very honest and skilled in delivering a complex topic to a less than skilled audience. That’s hard.

Ophidian couldn’t explain himself to Monkshood.

PAH - Ndn is a troll. His views are contrary and malicious. Avacta have never once said that AVA should be on the shelf. We ALL know that it requires a trial as the risk of accumulation are known. He uses Avacta to continue a childish feud (one sided) with Ophidian and Myles.

Wondergoals - Exactly. It’s as transparent as glass.

For the life of me, I can’t understand how he’s not banned. Which is the essence of my note to LSE. Plus evidence, of course.

So now they shouldn’t even bother with AVA6K?

Reported. Note sent direct to LSE.

No, that’s not being touted. You’ve been reminded of this on nervous occasions.

You cleverly try to troll within the ‘rules’ of stock discussion. I’ll now continue to report until you receive your deserved ban.

Not one person is bothered about how content you are with your investment, or why you hold. Everyone has reasons personal to them. Nobody cares.

Look. Forget the science stuff - nobody on this board has an upper hand in what we’re likely to see in the trials - whatever their background. We’re relying on Avacta - they’re quite good.

We’re after milestones. Nobody is expecting to be millionaires once does escalation is RNS’d. Stop twisting the narrative. We all KNOW that when dose escalation is RNS’d, we’ll have clear indication that the trial is safe to progress and gets us closer to the end goal. Some risk is removed.

Please; if you have a problem with Ophidian and Myles, send a note to your head teacher. They’ll take it up with your parents.

Extensive study across a broad range of ‘leading’ antigen tests.

It’s again clear how well our test performs at moderate to low viral loads;

‘Across all Ag-RDTs sensitivity was markedly better on samples with lower Ct-values, i.e., <20 (96.5%, CI 92.6 to 98.4) and <25 (95.8%, CI 92.3 to 97.8), in comparison to those with Ct =25 (50.7%, CI 35.6 to 65.8) and =30 (20.9%, CI 12.5 to 32.8)’

It also highlights how positive the results are when conducted by FINDdx, compared with other independent reviews.

https://www.medrxiv.org/content/10.1101/2021.02.26.21252546v2.full-text

Spud searching no less. Oh my.

Mowzerrocks - he has an agenda. Like Ndn, they talk about co treaty views, and this is a place for discussion etc. Thing is, nobody wants to discuss anything with them.

You need your own board mate. Breath of fresh air.

V2 has been compared via independent study - it’s still very poor.

Speculation is SureScreen - It would some up the position of Gov to declare their test ‘very good’. It’s real world clinical evaluation is woeful. It would t get close to passing desktop review.

But… we’re dealing with HMG. It’ll be awesome and fly through.

Could be. But the onshoring comment is why we’re best concentrating on the EU.

Thanks Poirot.

Wyn - let it go. You’re now using Ndn’s choice of words in your sermons. No, don’t worry, I’m not suggesting you’re the same person.

OK - the facts. The market has discounted profits from the LFT to date. It doesn’t appreciate it, hell, it has your view of it being a missed opportunity. Well done.

Genuinely - can you you just leave it now. Nothing else to discuss. You win. Any RNS referring to the LFT is a bonus. Repeat, you’re right.

Icecool - great find. Thanks for sharing. Exactly what the naysayers said COULDN’T happen.

Timster - this isn’t about TT being complete. We’ve seen that clip. It’s the assertion that ADBX are currently selling capacity.